Next 10 |
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...
2024-05-13 13:07:36 ET More on GameStop: GameStop: Approaching An Optimistic Fair Value But Not There Yet GameStop: Operations Are Stabilizing, But Expect More Pain To Come GameStop: Compelling Risk To Reward Profile Ahead Of Q4 Earnings GameStop's sudden mem...
2024-05-13 11:49:09 ET Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Conference Call May 13, 2024, 8:30 am ET Company Participants Chris Calabrese - MD, LifeSci Advisors Ted White - President & CEO Joe Bonaccorso - CCO Terry Kohler - CFO Gary ...
2024-05-13 07:45:22 ET More on Verrica Pharmaceuticals Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript Verrica Pharma gains as FDA lists Ycanth in Orange Book Seeking Alpha’s Quant Rating on Verrica Pharmaceuticals Historical earni...
– Reports YCANTH ® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 i...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Ve...
WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host ...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...